Our Dual Lens Approach

BVGH has a unique perspective – we look at the health problems facing poor countries through a dual lens of expertise in both global health and the biopharmaceutical industry.
Learn More»

Image
 
Image
  
  

Press Releases

We are busy faciliating global health partnerships and will post more news soon....stay tuned!
 

Updates on BIO Ventures for Global Health's initiatives

October 30, 2012

WIPO Re:Search Marks One Year Anniversary with Significant Growth and Promise

One year after its launch, WIPO Re:Search has doubled its membership and resulted in ten research collaborations or agreement. Members of WIPO Re:Search are meeting in Geneva today to take stock of the year’s progress and explore strategies to expand on the initiative’s success... Read full press release...

August 23, 2012

First Agreements Concluded under WIPO Re:Search for  Research on Neglected Tropical Diseases

Research to develop treatments for neglected tropical diseases recevied a boost this month as AstraZeneca concluded agreements through WIPO Re:Search with iThemba Pharmacueticals (South Africa), the University of California at San Francisco (U.S.), the University of Dundee (UK). The three agreements are the first partnerships established under the WIPO Re:Search initiative -- an unprecedented collaboration... Read full press release...

June 18, 2012

New Report Finds Biotechnology Companies are Participating in 39% of All Projects in Development for New Medicines and Technologies for Neglected Diseases

Small- to medium-sized biotechnology companies are bringing innovation to global health, according to a report published today by BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO). Read full press release ...

November 18, 2011

Don Joseph to succeed Dr. Melinda Moree as CEO of BIO Ventures for Global Health; Moree to become Executive Chair of the Board of Directors

BIO Ventures for Global Health (BVGH) announced today that Don Joseph, JD, currently the organization’s Chief Operating Officer, has been selected by the Board of Directors to assume the role of Chief Executive Officer effective February 1, 2012. Read full press release ...

October 26, 2011

Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for use in Treating Neglected Tropical Diseases as Part of WIPO Re:Search

The World Intellectual Property Organization (WIPO), in an unprecedented collaboration with leading pharmaceutical companies and BIO Ventures for Global Health (BVGH), launched today WIPO Re:Search, a new consortium where public and private sector organizations share valuable intellectual property (IP) and expertise with the global health research community to promote development of new drugs, vaccines, and diagnostics to treat neglected tropical diseases, malaria, and tuberculosis.  Read full press release ...

June 15, 2011

Leaders in Government, Biotechnology and Global Health Examine Innovative Ways to Accelerate Development of New Tools for Global Health

High-level members of the Obama Administration will gather with leaders from the biopharmaceutical and global health communities at the Partnering for Global Health Forum on June 27 to discuss ways to speed the development of new medical tools — drugs, vaccines and diagnostics — to address the most persistent challenges in global health.  Read full press release ...

March 15, 2011

NIH Director Dr. Francis Collins to Present Keynote Address at Partnering for Global Health Forum 2011

The Biotechnology Industry Organization (BIO) and BIO Ventures for Global Health (BVGH) announced today that Francis Collins, MD, PhD, Director of the National Institutes of Health, will provide the keynote address at the Partnering for Global Health Forum 2011. The conference will be co-located with the BIO International Convention and will be held June 27, 2011 at the Walter E. Washington Convention Center in Washington, DC.  Read full press release ...

October 11, 2010

Burrill & Company CEO and Genzyme Executive Join BVGH Board of Directors

BIO Ventures for Global Health (BVGH) announced today that G. Steven Burrill, Founder and Chief Executive Officer, Burrill & Company, and James A. Geraghty, Senior Vice President, Genzyme Corporation, have joined the organization’s Board of Directors. The addition of these two new board members rounds out the BVGH Board with a depth of expertise and experience in emerging markets and public-private partnerships.  Read full press release ...

August 16, 2010

Medicines for Malaria Venture Becomes First Product Development Partnership to Contribute Patents to the Pool for Open Innovation against Neglected Tropical Diseases

The Medicines for Malaria Venture (MMV) today became the first product development partnership (PDP) to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases. MMV joins GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in contributing to the Pool, which is administered by BIO Ventures for Global Health (BVGH).  Read full press release...

July 20, 2010

BIO Ventures for Global Health Opens San Francisco Office; Hires New Senior Staff

BIO Ventures for Global Health (BVGH) announced today that it is expanding to the West Coast with the opening of a new San Francisco headquarters office. The expansion provides BVGH the opportunity to work even more closely with the world class biotech and investor communities on both coasts.  Read full press release...

May 5, 2010

Massachusetts Institute of Technology (MIT) Joins Pool for Open Innovation against Neglected Tropical Diseases

The Massachusetts Institute of Technology (MIT) today became the first academic institution to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases. MIT joins GlaxoSmithKline (GSK) and Alnylam Pharmaceuticals, Inc. in contributing patents to the pool, which is administered by BIO Ventures for Global Health (BVGH). The Pool for Open Innovation seeks to motivate innovative and efficient drug discovery and development by opening access to intellectual property or knowhow in neglected tropical disease research. MIT’s contribution of patents to the pool is a landmark step from one of the world’s leading research institutions toward providing access to intellectual property for use by neglected tropical disease researchers. Read full press release...

May 5, 2010

South Africa Becomes First Government to Use the Pool for Open Innovation to Stimulate Neglected Disease Drug Research and Development

 South Africa’s Technology Innovation Agency (TIA) today became the first government agency to join in the Pool for Open Innovation against Neglected Tropical Diseases. TIA intends to use intellectual property and know-how from the pool to accelerate its efforts to grow the South African biotechnology sector and enhance the quality of life of those affected by neglected tropical diseases. Initially, TIA will focus on developing new medicines for tuberculosis and malaria. Read full press release...

May 3, 2010

Partnering for Global Health Forum Spurs Companies to Engage in Global Health

More than 250 global health, biopharmaceutical, academic, and donor organization leaders gathered in Chicago today (with more than 380 participating online via webcast) to share innovative ideas and best practices to speed the development of new drugs, vaccines, and diagnostics for the world’s poorest. Read full press release...

April 14, 2010

Partnering for Global Health Forum Announced

The Biotechnology Industry Organization (BIO) and BIO Ventures for Global Health (BVGH) announce the Partnering for Global Health Forum, an international partnering conference beginning May 3 and co-located with the BIO International Convention in Chicago, Ill. The Partnering for Global Health Forum will connect people and ideas to save lives in the developing world and focus on market-based solutions that will help speed the development of drugs, vaccines and diagnostics for the world's poorest people. The Forum will take place at the McCormick Place Lakeside Center.  Read full press release ...

April 6, 2010

BIO Ventures for Global Health Announces New Chief Operating Officer and Director

BIO Ventures for Global Health announced today that Donald R. Joseph, JD, has been named Chief Operating Officer (COO) and a member of the board of directors of the global health non-profit. Joseph brings to the organization a wealth of experience in the biopharmaceutical industry. Read full press release ...

January 20, 2010

BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool

BIO Ventures for Global Health, GlaxoSmithKline (GSK), and Alnylam announced today that the organizations are partnering to engage the global health community in using the powerful resources of the GSK and Alnylam Intellectual Property (IP) Pool. The IP Pool was formed in February 2009 to aid in the discovery and development of new medicines for the treatment of 16 neglected tropical diseases, as defined by the U.S. Food and Drug Administration, in the world’s least developed countries. Read full press release...

December 30, 2009

BVGH Announces New CEO

BIO Ventures for Global Health (BVGH) announced today that Melinda Moree, PhD, has been named Chief Executive Officer of the global health non-profit. Moree has served as interim CEO of BIO Ventures for Global Health since July 2009 and has been a member of the board of directors since the organization's inception in 2004. Read full press release...

September 15, 2009

BVGH Announces New Board Chair

BIO Ventures for Global Health (BVGH) announced today that Carl B. Feldbaum, Esq., was elected chairman of the global health non-profit’s Board of Directors. Feldbaum has served on the BVGH Board of Directors since its inception in 2004. Read full press release...

June 25, 2009

BVGH Announces Management Changes

BIO Ventures for Global Health (BVGH) today announced that Christopher D. Earl, PhD, will resign from BVGH, effective July 9, 2009. Melinda Moree, PhD, a member of the board since BVGH’s inception, will serve as interim CEO until a permanent replacement is hired. Read full press release...

October 20, 2008

FDA Issues Draft Guidance on Priority Review Vouchers

BIO Ventures for Global Health (BVGH) today announced its support of the US Food and Drug Administration's (FDA) release of Draft Guidance for Industry on Priority Review Vouchers. The Priority Review Voucher (PRV) program is designed to encourage industry investment in the development of drugs and vaccines for neglected tropical diseases. Read full press release...

October 14, 2008

 BVGH Receives $7M Grant from Gates Foundation

BIO Ventures for Global Health (BVGH) today announced that the Bill & Melinda Gates Foundation has expanded its support of the organization, so it can further engage biotechnology industry innovation to create new medicines for infectious diseases of the developing world. The $7 million grant will help BVGH build the market case for biotechnology industry investment through market-based incentives and to create new opportunities for R&D collaborations.  Read full press release...

February 20, 2008

Senator Sam Brownback to Speak at Global Health Partnering Forum

The Biotechnology Industry Organization (BIO) and BIO Ventures for Global Health (BVGH) are pleased to announce U.S. Senator Sam Brownback, R-Kan., will deliver the Breakfast Plenary, “Incentives to Drive Innovation,” at the Partnering for Global Health Forum 2008, to be held March 11-12 near Washington, D.C.  Read full press release...

January 24, 2008

Partnering for Global Health Forum 2008 to Create a New Paradigm to Address Pressing Global Health Issues

The Biotechnology Industry Organization (BIO) and BIO Ventures for Global Health (BVGH) are pleased to announce that Anthony Fauci, MD, of NIH’s National Institute of Allergy and Infectious Diseases will be delivering a roundtable on global health from bench to bedside, and Cheryl Scott of the Bill & Melinda Gates Foundation will be delivering a fireside chat on global health issues at the Partnering for Global Health Forum, co-sponsored by the Gates Foundation.  Read full press release ...

May 8 , 2007

BVGH and BIO Launch Initiative to Engage Biotech Companies in Global Health R&D

BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO) today unveiled plans to co-host the Partnering for Global Health Forum 2008. Read full press release...

February 9, 2007

BIO Ventures for Global Health Commends the Launch of First Advance Market Commitment

BIO Ventures for Global Health (BVGH) commends today’s launch of the first Advance Market Commitment (AMC), a novel financing mechanism to encourage industry investment in much-needed vaccines for the developing world. Read full press release...

October 20, 2006

BIO Ventures for Global Health Study Identifies Significant Market for Tuberculosis Vaccines

According to a groundbreaking study released today by BIO Ventures for Global Health (BVGH), a vaccine to prevent tuberculosis presents a significant opportunity for industry investment with a potential global market of US $450 million to nearly $1 billion. Read full press release...

May 24, 2006

BIO Ventures for Global Health Announces Appointment of Julie Klim as Vice President of Business Development

BIO Ventures for Global Health (BVGH) announced the appointment today of Julie Klim, previously Co-Founder and Principal at Capital Royalty L.P., as Vice President of Business Development. Read full press release...

October 3, 2005

BIO Ventures for Global Health Announces Appointment of Christopher Earl As New CEO

BIO Ventures for Global Health (BVGH) today announced that Christopher D. Earl, PhD, a leading venture capitalist and entrepreneur in the biotechnology industry, has been appointed president, chief executive officer and director of BVGH.  Dr. Earl was previously managing director at the Perseus-Soros BioPharmaceutical Fund.  Read full press release...

June 21, 2005

BIO Ventures for Global Health Announces Bill & Melinda Gates Foundation Grant to Expand Biotech Industry’s Role in Fight Against Neglected Diseases

BIO Ventures for Global Health today announced it will expand its efforts to enlist biotechnology companies in the fight to improve global health, with a new $5.4 million grant from the Bill & Melinda Gates Foundation.  The announcement was made at BIO 2005, the biotech industry’s annual convention. Read full press release...

June 7, 2004

BIO Launches BIO Ventures for Global Health With Initial Grant from Bill & Melinda Gates Foundation

The Biotechnology Industry Organization (BIO) today announced the launch of BIO Ventures for Global Health (BVGH), a new nonprofit organization that will work to enlist the biotechnology industry in the fight against neglected diseases. BVGH has received a $1 million start-up grant from the Bill & Melinda Gates Foundation... Read full press release...

May 3, 2004

Biotech's Role in Improving Global Health

The biotechnology industry is working to overcome hurdles to provide patients in the developing world with the significant medicines it has created to battle such devastating diseases as AIDS, malaria and tuberculosis. BIO 2004, the Biotechnology Industry Organization's (BIO's) Annual International Convention, which will take place June 6-9 at San Francisco's Moscone Center, will feature... Read full press release...